Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 915 entries
Sorted by: Best Match Show Resources per page
Second International Congress on Schizophrenia Research. San Diego, California, April 1-5, 1989. Abstracts.

Schizophrenia research

[No authors listed]
PMID: 2577216
Schizophr Res. 1989 Jan-Apr;2(1):1-250.

No abstract available.

Cite
Second International Congress on Schizophrenia Research. San Diego, California, April 1-5, 1989. Abstracts. Schizophr Res. 1989;2(1):1-250
(1989). Second International Congress on Schizophrenia Research. San Diego, California, April 1-5, 1989. Abstracts. Schizophrenia research, 2(1), 1-250.
"Second International Congress on Schizophrenia Research. San Diego, California, April 1-5, 1989. Abstracts." Schizophrenia research vol. 2,1 (1989): 1-250.
Second International Congress on Schizophrenia Research. San Diego, California, April 1-5, 1989. Abstracts. Schizophr Res. 1989 Jan-Apr;2(1):1-250. PMID: 2577216.
Copy Download .nbib Format: NLM
Treatment and causes of schizophrenia. Proceedings of the VA Medical Research Service Symposium. Denver, Co, October 23, 1989.

Schizophrenia research

[No authors listed]
PMID: 2039763
Schizophr Res. 1991 Mar-Apr;4(2):67-243.

No abstract available.

Cite
Treatment and causes of schizophrenia. Proceedings of the VA Medical Research Service Symposium. Denver, Co, October 23, 1989. Schizophr Res. 1991;4(2):67-243
(1991). Treatment and causes of schizophrenia. Proceedings of the VA Medical Research Service Symposium. Denver, Co, October 23, 1989. Schizophrenia research, 4(2), 67-243.
"Treatment and causes of schizophrenia. Proceedings of the VA Medical Research Service Symposium. Denver, Co, October 23, 1989." Schizophrenia research vol. 4,2 (1991): 67-243.
Treatment and causes of schizophrenia. Proceedings of the VA Medical Research Service Symposium. Denver, Co, October 23, 1989. Schizophr Res. 1991 Mar-Apr;4(2):67-243. PMID: 2039763.
Copy Download .nbib Format: NLM
Cognitive training for schizophrenia in developing countries: a pilot trial in Brazil.

Schizophrenia research and treatment

Pontes LM, Martins CB, Napolitano IC, Fonseca JR, Oliveira GM, Iso SM, Menezes AK, Vizzotto AD, di Sarno ES, Elkis H.
PMID: 24288608
Schizophr Res Treatment. 2013;2013:321725. doi: 10.1155/2013/321725. Epub 2013 Oct 30.

Cognitive deficits in schizophrenia can massively impact functionality and quality of life, furthering the importance of cognitive training. Despite the development of the field in Europe and in the United States, no programmes have been developed and tested in...

Cite
Pontes LM, Martins CB, Napolitano IC, et al. Cognitive training for schizophrenia in developing countries: a pilot trial in Brazil. Schizophr Res Treatment. 2013;2013:321725doi: 10.1155/2013/321725.
Pontes, L. M., Martins, C. B., Napolitano, I. C., Fonseca, J. R., Oliveira, G. M., Iso, S. M., Menezes, A. K., Vizzotto, A. D., di Sarno, E. S., & Elkis, H. (2013). Cognitive training for schizophrenia in developing countries: a pilot trial in Brazil. Schizophrenia research and treatment, 2013321725. https://doi.org/10.1155/2013/321725
Pontes, Livia M M, et al. "Cognitive training for schizophrenia in developing countries: a pilot trial in Brazil." Schizophrenia research and treatment vol. 2013 (2013): 321725. doi: https://doi.org/10.1155/2013/321725
Pontes LM, Martins CB, Napolitano IC, Fonseca JR, Oliveira GM, Iso SM, Menezes AK, Vizzotto AD, di Sarno ES, Elkis H. Cognitive training for schizophrenia in developing countries: a pilot trial in Brazil. Schizophr Res Treatment. 2013;2013:321725. doi: 10.1155/2013/321725. Epub 2013 Oct 30. PMID: 24288608; PMCID: PMC3833062.
Copy Download .nbib Format: NLM
Sex Differences in Severity, Social Functioning, Adherence to Treatment, and Cognition of Adolescents with Schizophrenia.

Schizophrenia research and treatment

Pérez-Garza R, Victoria-Figueroa G, Ulloa-Flores RE.
PMID: 27703813
Schizophr Res Treatment. 2016;2016:1928747. doi: 10.1155/2016/1928747. Epub 2016 Sep 14.

No abstract available.

Cite
Pérez-Garza R, Victoria-Figueroa G, Ulloa-Flores RE. Sex Differences in Severity, Social Functioning, Adherence to Treatment, and Cognition of Adolescents with Schizophrenia. Schizophr Res Treatment. 2016;2016:1928747doi: 10.1155/2016/1928747.
Pérez-Garza, R., Victoria-Figueroa, G., & Ulloa-Flores, R. E. (2016). Sex Differences in Severity, Social Functioning, Adherence to Treatment, and Cognition of Adolescents with Schizophrenia. Schizophrenia research and treatment, 20161928747. https://doi.org/10.1155/2016/1928747
Pérez-Garza, Rodolfo, et al. "Sex Differences in Severity, Social Functioning, Adherence to Treatment, and Cognition of Adolescents with Schizophrenia." Schizophrenia research and treatment vol. 2016 (2016): 1928747. doi: https://doi.org/10.1155/2016/1928747
Pérez-Garza R, Victoria-Figueroa G, Ulloa-Flores RE. Sex Differences in Severity, Social Functioning, Adherence to Treatment, and Cognition of Adolescents with Schizophrenia. Schizophr Res Treatment. 2016;2016:1928747. doi: 10.1155/2016/1928747. Epub 2016 Sep 14. PMID: 27703813; PMCID: PMC5039268.
Copy Download .nbib Format: NLM
In This Issue September 2017.

Schizophrenia research

DeLisi LE.
PMID: 28982604
Schizophr Res. 2017 Oct;188:1-2. doi: 10.1016/j.schres.2017.09.009.

No abstract available.

Cite
DeLisi LE. In This Issue September 2017. Schizophr Res. 2017;188:1-2doi: 10.1016/j.schres.2017.09.009.
DeLisi, L. E. (2017). In This Issue September 2017. Schizophrenia research, 1881-2. https://doi.org/10.1016/j.schres.2017.09.009
DeLisi, Lynn E. "In This Issue September 2017." Schizophrenia research vol. 188 (2017): 1-2. doi: https://doi.org/10.1016/j.schres.2017.09.009
DeLisi LE. In This Issue September 2017. Schizophr Res. 2017 Oct;188:1-2. doi: 10.1016/j.schres.2017.09.009. PMID: 28982604.
Copy Download .nbib Format: NLM
Arousal Predisposition as a Vulnerability Indicator for Psychosis: A General Population Online Stress Induction Study.

Schizophrenia research and treatment

Clamor A, Warmuth AM, Lincoln TM.
PMID: 26199758
Schizophr Res Treatment. 2015;2015:725136. doi: 10.1155/2015/725136. Epub 2015 Jun 23.

Explanatory models ascribe to arousability a central role for the development of psychotic symptoms. Thus, a disposition to hyperarousal (i.e., increased arousal predisposition (AP)) may serve as an underlying vulnerability indicator for psychosis by interacting with stressors to cause...

Cite
Clamor A, Warmuth AM, Lincoln TM. Arousal Predisposition as a Vulnerability Indicator for Psychosis: A General Population Online Stress Induction Study. Schizophr Res Treatment. 2015;2015:725136doi: 10.1155/2015/725136.
Clamor, A., Warmuth, A. M., & Lincoln, T. M. (2015). Arousal Predisposition as a Vulnerability Indicator for Psychosis: A General Population Online Stress Induction Study. Schizophrenia research and treatment, 2015725136. https://doi.org/10.1155/2015/725136
Clamor, Annika, et al. "Arousal Predisposition as a Vulnerability Indicator for Psychosis: A General Population Online Stress Induction Study." Schizophrenia research and treatment vol. 2015 (2015): 725136. doi: https://doi.org/10.1155/2015/725136
Clamor A, Warmuth AM, Lincoln TM. Arousal Predisposition as a Vulnerability Indicator for Psychosis: A General Population Online Stress Induction Study. Schizophr Res Treatment. 2015;2015:725136. doi: 10.1155/2015/725136. Epub 2015 Jun 23. PMID: 26199758; PMCID: PMC4493307.
Copy Download .nbib Format: NLM
The ACIPS: Moving forward in the assessment of negative symptoms.

Schizophrenia research

Gooding DC, Pflum MJ.
PMID: 27372254
Schizophr Res. 2016 Oct;176(2):327-328. doi: 10.1016/j.schres.2016.06.002. Epub 2016 Jun 29.

No abstract available.

Cite
Gooding DC, Pflum MJ. The ACIPS: Moving forward in the assessment of negative symptoms. Schizophr Res. 2016;176(2):327-328doi: 10.1016/j.schres.2016.06.002.
Gooding, D. C., & Pflum, M. J. (2016). The ACIPS: Moving forward in the assessment of negative symptoms. Schizophrenia research, 176(2), 327-328. https://doi.org/10.1016/j.schres.2016.06.002
Gooding, Diane Carol, and Pflum, Madeline Johnson. "The ACIPS: Moving forward in the assessment of negative symptoms." Schizophrenia research vol. 176,2 (2016): 327-328. doi: https://doi.org/10.1016/j.schres.2016.06.002
Gooding DC, Pflum MJ. The ACIPS: Moving forward in the assessment of negative symptoms. Schizophr Res. 2016 Oct;176(2):327-328. doi: 10.1016/j.schres.2016.06.002. Epub 2016 Jun 29. PMID: 27372254.
Copy Download .nbib Format: NLM
POSITIVE AND NEGATIVE SUBCLINICAL SYMPTOMS AND MCCB PERFORMANCE IN NON-PSYCHIATRIC CONTROLS.

Schizophrenia research. Cognition

Korponay C, Nitzburg GC, Malhotra AK, DeRosse P.
PMID: 25530948
Schizophr Res Cogn. 2014 Dec 01;1(4):175-179. doi: 10.1016/j.scog.2014.09.002.

Considerable data support the phenomenological and temporal continuity between subclinical psychosis and psychotic disorders. In recent years, neurocognitive deficits have increasingly been recognized as a core feature of psychotic illness but there are few data seeking to elucidate the...

Cite
Korponay C, Nitzburg GC, Malhotra AK, et al. POSITIVE AND NEGATIVE SUBCLINICAL SYMPTOMS AND MCCB PERFORMANCE IN NON-PSYCHIATRIC CONTROLS. Schizophr Res Cogn. 2014;1(4):175-179doi: 10.1016/j.scog.2014.09.002.
Korponay, C., Nitzburg, G. C., Malhotra, A. K., & DeRosse, P. (2014). POSITIVE AND NEGATIVE SUBCLINICAL SYMPTOMS AND MCCB PERFORMANCE IN NON-PSYCHIATRIC CONTROLS. Schizophrenia research. Cognition, 1(4), 175-179. https://doi.org/10.1016/j.scog.2014.09.002
Korponay, Cole, et al. "POSITIVE AND NEGATIVE SUBCLINICAL SYMPTOMS AND MCCB PERFORMANCE IN NON-PSYCHIATRIC CONTROLS." Schizophrenia research. Cognition vol. 1,4 (2014): 175-179. doi: https://doi.org/10.1016/j.scog.2014.09.002
Korponay C, Nitzburg GC, Malhotra AK, DeRosse P. POSITIVE AND NEGATIVE SUBCLINICAL SYMPTOMS AND MCCB PERFORMANCE IN NON-PSYCHIATRIC CONTROLS. Schizophr Res Cogn. 2014 Dec 01;1(4):175-179. doi: 10.1016/j.scog.2014.09.002. PMID: 25530948; PMCID: PMC4266935.
Copy Download .nbib Format: NLM
Neuroscience-informed Auditory Training in Schizophrenia: A Final Report of the Effects on Cognition and Serum Brain-Derived Neurotrophic Factor.

Schizophrenia research. Cognition

Fisher M, Mellon SH, Wolkowitz O, Vinogradov S.
PMID: 26705516
Schizophr Res Cogn. 2016 Mar 01;3:1-7. doi: 10.1016/j.scog.2015.10.006.

OBJECTIVE: We previously reported the interim effects in a per protocol analysis of a randomized controlled trial of an innovative neuroscience-informed computerized cognitive training approach in schizophrenia. Here we report the effects of training on behavioral outcome measures in...

Cite
Fisher M, Mellon SH, Wolkowitz O, et al. Neuroscience-informed Auditory Training in Schizophrenia: A Final Report of the Effects on Cognition and Serum Brain-Derived Neurotrophic Factor. Schizophr Res Cogn. 2016;3:1-7doi: 10.1016/j.scog.2015.10.006.
Fisher, M., Mellon, S. H., Wolkowitz, O., & Vinogradov, S. (2016). Neuroscience-informed Auditory Training in Schizophrenia: A Final Report of the Effects on Cognition and Serum Brain-Derived Neurotrophic Factor. Schizophrenia research. Cognition, 31-7. https://doi.org/10.1016/j.scog.2015.10.006
Fisher, Melissa, et al. "Neuroscience-informed Auditory Training in Schizophrenia: A Final Report of the Effects on Cognition and Serum Brain-Derived Neurotrophic Factor." Schizophrenia research. Cognition vol. 3 (2016): 1-7. doi: https://doi.org/10.1016/j.scog.2015.10.006
Fisher M, Mellon SH, Wolkowitz O, Vinogradov S. Neuroscience-informed Auditory Training in Schizophrenia: A Final Report of the Effects on Cognition and Serum Brain-Derived Neurotrophic Factor. Schizophr Res Cogn. 2016 Mar 01;3:1-7. doi: 10.1016/j.scog.2015.10.006. PMID: 26705516; PMCID: PMC4685735.
Copy Download .nbib Format: NLM
Utility of Two PANSS 5-Factor Models for Assessing Psychosocial Outcomes in Clinical Programs for Persons with Schizophrenia.

Schizophrenia research and treatment

Jerrell JM, Hrisko S.
PMID: 24381761
Schizophr Res Treatment. 2013;2013:705631. doi: 10.1155/2013/705631. Epub 2013 Dec 05.

Using symptom factors derived from two models of the Positive and Negative Syndrome Scale (PANSS) as covariates, change over time in consumer psychosocial functioning, medication adherence/compliance, and treatment satisfaction outcomes are compared based on a randomized, controlled trial assessing...

Cite
Jerrell JM, Hrisko S. Utility of Two PANSS 5-Factor Models for Assessing Psychosocial Outcomes in Clinical Programs for Persons with Schizophrenia. Schizophr Res Treatment. 2013;2013:705631doi: 10.1155/2013/705631.
Jerrell, J. M., & Hrisko, S. (2013). Utility of Two PANSS 5-Factor Models for Assessing Psychosocial Outcomes in Clinical Programs for Persons with Schizophrenia. Schizophrenia research and treatment, 2013705631. https://doi.org/10.1155/2013/705631
Jerrell, Jeanette M, and Hrisko, Stephanie. "Utility of Two PANSS 5-Factor Models for Assessing Psychosocial Outcomes in Clinical Programs for Persons with Schizophrenia." Schizophrenia research and treatment vol. 2013 (2013): 705631. doi: https://doi.org/10.1155/2013/705631
Jerrell JM, Hrisko S. Utility of Two PANSS 5-Factor Models for Assessing Psychosocial Outcomes in Clinical Programs for Persons with Schizophrenia. Schizophr Res Treatment. 2013;2013:705631. doi: 10.1155/2013/705631. Epub 2013 Dec 05. PMID: 24381761; PMCID: PMC3871510.
Copy Download .nbib Format: NLM
Delusional Disorder over the Reproductive Life Span: The Potential Influence of Menopause on the Clinical Course.

Schizophrenia research and treatment

González-Rodríguez A, Molina-Andreu O, Penadés R, Garriga M, Pons A, Catalán R, Bernardo M.
PMID: 26600949
Schizophr Res Treatment. 2015;2015:979605. doi: 10.1155/2015/979605. Epub 2015 Oct 27.

Background and Objectives. Recent evidence supports an association between estrogen levels and severity of psychopathology in schizophrenia women. Our main goal was to investigate whether delusional disorder (DD) women with premenopausal onset and those with postmenopausal onset differ in...

Cite
González-Rodríguez A, Molina-Andreu O, Penadés R, et al. Delusional Disorder over the Reproductive Life Span: The Potential Influence of Menopause on the Clinical Course. Schizophr Res Treatment. 2015;2015:979605doi: 10.1155/2015/979605.
González-Rodríguez, A., Molina-Andreu, O., Penadés, R., Garriga, M., Pons, A., Catalán, R., & Bernardo, M. (2015). Delusional Disorder over the Reproductive Life Span: The Potential Influence of Menopause on the Clinical Course. Schizophrenia research and treatment, 2015979605. https://doi.org/10.1155/2015/979605
González-Rodríguez, Alexandre, et al. "Delusional Disorder over the Reproductive Life Span: The Potential Influence of Menopause on the Clinical Course." Schizophrenia research and treatment vol. 2015 (2015): 979605. doi: https://doi.org/10.1155/2015/979605
González-Rodríguez A, Molina-Andreu O, Penadés R, Garriga M, Pons A, Catalán R, Bernardo M. Delusional Disorder over the Reproductive Life Span: The Potential Influence of Menopause on the Clinical Course. Schizophr Res Treatment. 2015;2015:979605. doi: 10.1155/2015/979605. Epub 2015 Oct 27. PMID: 26600949; PMCID: PMC4639664.
Copy Download .nbib Format: NLM
Drug Repurposing Is a New Opportunity for Developing Drugs against Neuropsychiatric Disorders.

Schizophrenia research and treatment

Lee HM, Kim Y.
PMID: 27073698
Schizophr Res Treatment. 2016;2016:6378137. doi: 10.1155/2016/6378137. Epub 2016 Mar 17.

Better the drugs you know than the drugs you do not know. Drug repurposing is a promising, fast, and cost effective method that can overcome traditional de novo drug discovery and development challenges of targeting neuropsychiatric and other disorders....

Cite
Lee HM, Kim Y. Drug Repurposing Is a New Opportunity for Developing Drugs against Neuropsychiatric Disorders. Schizophr Res Treatment. 2016;2016:6378137doi: 10.1155/2016/6378137.
Lee, H. M., & Kim, Y. (2016). Drug Repurposing Is a New Opportunity for Developing Drugs against Neuropsychiatric Disorders. Schizophrenia research and treatment, 20166378137. https://doi.org/10.1155/2016/6378137
Lee, Hyeong-Min, and Kim, Yuna. "Drug Repurposing Is a New Opportunity for Developing Drugs against Neuropsychiatric Disorders." Schizophrenia research and treatment vol. 2016 (2016): 6378137. doi: https://doi.org/10.1155/2016/6378137
Lee HM, Kim Y. Drug Repurposing Is a New Opportunity for Developing Drugs against Neuropsychiatric Disorders. Schizophr Res Treatment. 2016;2016:6378137. doi: 10.1155/2016/6378137. Epub 2016 Mar 17. PMID: 27073698; PMCID: PMC4814692.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 915 entries